MET and melanoma: Mutations occurred in tumor types as expected: KRAS mutations were mainly observed in colorectal carcinoma (43%) [38] and lung cancer (22%) [1]; melanoma patients showed a high frequency of BRAF (56%) and NRAS (20%) mutations [39–41]; EGFR (12%), ERBB2 (1%), and MET (1%) mutations could be mainly attributed to lung cancer samples [1]; almost all samples suspected of GIST showed a mutation (91%) in KIT (68%) or PDGFRA (23%) [42].